Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $204.00

Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by equities researchers at Citigroup from $203.00 to $204.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Citigroup’s price target points to a potential upside of 64.97% from the stock’s current price.

Several other equities analysts also recently issued reports on NBIX. Zacks Research downgraded shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Monday, December 29th. Canaccord Genuity Group upped their price objective on shares of Neurocrine Biosciences from $160.00 to $164.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. Needham & Company LLC lowered their target price on Neurocrine Biosciences from $187.00 to $185.00 and set a “buy” rating for the company in a report on Thursday. Truist Financial cut their price target on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a “buy” rating on the stock in a research report on Thursday, January 8th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Neurocrine Biosciences in a report on Thursday, January 22nd. Fifteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $177.56.

Neurocrine Biosciences Price Performance

Shares of NASDAQ NBIX traded down $13.78 during trading hours on Thursday, hitting $123.66. 2,575,708 shares of the stock were exchanged, compared to its average volume of 1,162,729. The company’s 50 day moving average is $141.39 and its 200 day moving average is $140.58. The firm has a market capitalization of $12.33 billion, a P/E ratio of 29.48, a P/E/G ratio of 0.65 and a beta of 0.31. Neurocrine Biosciences has a one year low of $84.23 and a one year high of $160.18.

Insider Buying and Selling

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 4,376 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $159.65, for a total value of $698,628.40. Following the completion of the transaction, the insider directly owned 43,405 shares in the company, valued at approximately $6,929,608.25. This represents a 9.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director George J. Morrow sold 15,000 shares of the company’s stock in a transaction dated Tuesday, November 25th. The stock was sold at an average price of $143.37, for a total transaction of $2,150,550.00. Following the completion of the transaction, the director owned 7,068 shares in the company, valued at approximately $1,013,339.16. The trade was a 67.97% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 61,966 shares of company stock valued at $8,625,166 in the last 90 days. Insiders own 4.80% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors have recently added to or reduced their stakes in the stock. USA Financial Formulas acquired a new position in shares of Neurocrine Biosciences during the 4th quarter worth approximately $25,000. Geneos Wealth Management Inc. grew its holdings in shares of Neurocrine Biosciences by 143.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock worth $25,000 after acquiring an additional 135 shares during the period. Golden State Wealth Management LLC boosted its holdings in shares of Neurocrine Biosciences by 120.5% during the third quarter. Golden State Wealth Management LLC now owns 183 shares of the company’s stock worth $26,000 after purchasing an additional 100 shares during the last quarter. Eastern Bank acquired a new position in shares of Neurocrine Biosciences during the 3rd quarter valued at $27,000. Finally, DJE Kapital AG purchased a new position in shares of Neurocrine Biosciences during the 4th quarter valued at approximately $28,000. 92.59% of the stock is owned by hedge funds and other institutional investors.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Company reiterated strong product sales and set 2026 Ingrezza sales guidance of $2.7–$2.8B, underscoring a durable commercial franchise that supports longer‑term upside. PR Newswire: Q4 Results & Guidance
• Positive Sentiment: Several analysts reiterated Buy/outperform ratings and high price targets (median target ~$179), signaling continued Wall Street confidence in the company’s pipeline and franchise despite near‑term noise. TipRanks: Analyst Notes
• Neutral Sentiment: Some firms made modest price‑target tweaks (e.g., Wedbush raised to $151, Needham nudged targets) — these are minor recalibrations within a broadly bullish analyst set and may have limited directional impact by themselves. Benzinga: Analyst Moves
• Negative Sentiment: Q4 EPS missed consensus (reported ~$1.88 vs. street estimates higher), which is a primary near‑term catalyst for selling pressure and re‑rating by short‑term traders. MarketBeat: Earnings Summary
• Negative Sentiment: Multiple price‑target downgrades/cuts issued this morning (RBC to $177, BMO to $140, HC Wainwright trimmed its target) likely amplified intra‑day selling despite unchanged buy/perform ratings. Benzinga: Morning PT Changes
• Negative Sentiment: Notable recent insider selling and some hedge‑fund rebalancing were flagged in coverage, which can increase downward pressure when combined with the quarter’s EPS miss. Quiver Quant: Stock Reaction & Insider Activity

Neurocrine Biosciences Company Profile

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.